

SUMMARY

Summary in terms of Regulation 13(1B) of the Competition Commission of India (Procedure in regard to the Transaction of Business relating to Combinations) Regulations, 2011 (as amended)

a) Names of parties of the combination

1. Abbott Laboratories (**Abbott**) and St. Jude Medical, Inc. (**SJM**) are the parties to the combination. Along with the parties, two newly incorporated wholly owned subsidiaries of Abbott Laboratories – Vault Merger Sub, LLC and Vault Merger Sub, Inc. – are also parties to the Agreement and Plan of Merger (**Agreement**) executed on 27 April 2016, which governs the terms of Abbott's acquisition of SJM.

b) Type of the combination

2. The proposed combination relates to the acquisition of SJM by Abbott, hereinafter referred to as the **Proposed Combination**.

c) Area of activity of the parties to the combination

Abbott:

3. Abbott is a publicly listed global healthcare company that researches, develops, manufactures, and sells a diversified range of healthcare products. It has four principal businesses:
 - a. **Nutritional Products:** These products comprise pediatric and adult nutritional products manufactured, marketed, and sold worldwide.

- b. **Medical Devices:** These products comprise vascular products, optical products, and diabetes care products. Vascular products include coronary, endovascular, vessel closure, and structural heart devices.
 - c. **Diagnostic Products:** These products comprise diagnostic systems and tests manufactured, marketed, and sold worldwide.
 - d. **Established Pharmaceutical Products:** These products comprise branded generic pharmaceuticals that are marketed and sold in developing markets.
4. SJM is a global medical device company that researches, develops, manufactures, and sells cardiovascular medical devices. It has five principal businesses:
- a. **Traditional Cardiac Rhythm Management Products:** These products include single and dual chamber pacemakers and implantable cardioverter defibrillators.
 - b. **Heart Failure Products:** These products include cardiac resynchronization devices, ventricular assist devices, and pulmonary artery pressure monitors.
 - c. **Cardiovascular Products:** These products include mechanical and tissue heart valves, patent foramen ovale closure devices, structural heart defect devices, vessel closure devices, pressure measurement guidewires,

diagnostic coronary imaging technology, diagnostic guidewires, percutaneous heart pumps, renal denervation technology, and vascular plugs.

d. **Atrial Fibrillation Products:** These products assist physicians in diagnosing and treating irregular heart rhythms. They include diagnostic and ablation catheters; recording, mapping, and navigation devices, and transseptal access devices.

e. **Neuromodulation Products:** These products provide neurostimulation therapy to treat chronic pain and movement disorders.

d) Relevant markets to which the combination relates

5. The Proposed Combination relates to the market for 'small hole' vessel closure solutions in India,